Home › Companies › Editas Medicine, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Editas Medicine, Inc.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 17, 2026: 4 items on Editas Medicine, Inc.’s Form 8-K, filed June 18, 2026: 2 approved · 2 passed (calculated).
Significant dissent: 1 director (27.4% against).
Notable dissent: 1 other board item (16.1% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Ra Capital Management, L.P. (13F, 5.8%, as of September 30, 2026)
Explore Editas Medicine, Inc. in the interactive database Compare manager voting policies
These tallies are Editas Medicine, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Bernadette Connaughton | 28,660,181 | -- | -- | 10,789,549 | 26,404,190 | 73% | Passed (calculated) | — |
| Elect Director: Elliott Levy, M.D. | 37,095,058 | -- | -- | 2,354,672 | 26,404,190 | 94% | Passed (calculated) | — |
| 2. The compensation paid to its named executive officers | 32,914,258 | 6,322,885 | 212,587 | -- | 26,404,190 | 84% | Approved | — |
| 3. The selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 64,686,839 | 774,471 | 392,610 | -- | 0 | 99% | Approved | — |
Source: Editas Medicine, Inc., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
237 asset managers disclosed a vote on at least one Editas Medicine, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
73% Majority: yes · of votes cast
Description as filed by funds: Election of two Class I Directors, each to serve until the 2029 annual meeting of stockholders: Bernadette Connaughton
Editas Medicine, Inc.’s own tally for this item (“Elect Director: Bernadette Connaughton”): 28,660,181 for, 10,789,549 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 73% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 47 asset managers below reported 13,679,209 for, 1,173,183 withheld, 1,827,587 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,313,083 | 0 | 61 | 13,693 | For |
| Fidelity | 2,140,598 | 0 | 0 | 42,900 | For |
| BlackRock | 306,602 | 0 | 1,653,431 | 0 | Mixed |
| TIAA | 1,903,318 | 0 | 0 | 0 | For |
| Charles Schwab | 862,565 | 0 | 0 | 0 | For |
| JPMorgan | 588,540 | 0 | 0 | 0 | For |
| Equitable | 0 | 0 | 0 | 259,336 | Withhold |
| Lincoln Financial | 127,677 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 126,000 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 119,137 | Withhold |
| Brighthouse | 77,282 | 0 | 0 | 32,151 | Mixed |
| SEI | 108,986 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 108,885 | 0 | Abstain |
| Columbia Threadneedle | 0 | 0 | 0 | 95,483 | Withhold |
| Global X | 92,273 | 0 | 0 | 0 | For |
| Nationwide | 3,341 | 0 | 0 | 86,738 | Withhold |
| Voya | 0 | 0 | 0 | 57,070 | Withhold |
| Northern Trust | 0 | 0 | 0 | 55,991 | Withhold |
| T. Rowe Price | 0 | 0 | 0 | 55,067 | Withhold |
| AQR | 0 | 0 | 0 | 41,896 | Withhold |
| Pacific Life | 0 | 0 | 0 | 40,292 | Withhold |
| Bridge Builder Trust | 0 | 0 | 39,850 | 0 | Abstain |
| Goldman Sachs | 0 | 0 | 0 | 37,079 | Withhold |
| Russell Investments | 36,657 | 0 | 0 | 0 | For |
| Invesco | 35,570 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of two Class I Directors, each to serve until the 2029 annual meeting of stockholders: Elliott Levy, M.D.
Editas Medicine, Inc.’s own tally for this item (“Elect Director: Elliott Levy, M.D.”): 37,095,058 for, 2,354,672 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 47 asset managers below reported 16,510,339 for, 169,635 withheld, 5 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,326,832 | 0 | 5 | 0 | For |
| Fidelity | 2,183,498 | 0 | 0 | 0 | For |
| BlackRock | 1,960,033 | 0 | 0 | 0 | For |
| TIAA | 1,903,318 | 0 | 0 | 0 | For |
| Charles Schwab | 862,565 | 0 | 0 | 0 | For |
| JPMorgan | 588,540 | 0 | 0 | 0 | For |
| Equitable | 154,726 | 0 | 0 | 104,610 | Mixed |
| Lincoln Financial | 127,677 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 126,000 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 119,137 | 0 | 0 | 0 | For |
| Brighthouse | 109,433 | 0 | 0 | 0 | For |
| SEI | 108,986 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 108,885 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 95,483 | 0 | 0 | 0 | For |
| Global X | 92,273 | 0 | 0 | 0 | For |
| Nationwide | 90,079 | 0 | 0 | 0 | For |
| Voya | 57,070 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 55,991 | Withhold |
| T. Rowe Price | 55,067 | 0 | 0 | 0 | For |
| AQR | 41,896 | 0 | 0 | 0 | For |
| Pacific Life | 40,292 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 39,850 | 0 | 0 | 0 | For |
| Goldman Sachs | 37,079 | 0 | 0 | 0 | For |
| Russell Investments | 36,657 | 0 | 0 | 0 | For |
| Invesco | 35,570 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
84% Approved · of votes cast
Prior year: 61.1% for (May 29, 2025 meeting) ▲ 22.8 pts
Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS.
Editas Medicine, Inc.’s own tally for this item (“2. The compensation paid to its named executive officers”): 32,914,258 for, 6,322,885 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation paid to its named executive officers.”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,326,802 | 33 | 1 | 0 | For |
| Fidelity | 2,140,598 | 42,900 | 0 | 0 | For |
| BlackRock | 1,960,033 | 0 | 0 | 0 | For |
| TIAA | 1,903,318 | 0 | 0 | 0 | For |
| Charles Schwab | 862,565 | 0 | 0 | 0 | For |
| JPMorgan | 588,540 | 0 | 0 | 0 | For |
| Equitable | 154,726 | 104,610 | 0 | 0 | Mixed |
| Lincoln Financial | 127,677 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 126,000 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 119,137 | 0 | 0 | Against |
| Brighthouse | 77,282 | 32,151 | 0 | 0 | Mixed |
| SEI | 108,986 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 108,885 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 95,483 | 0 | 0 | Against |
| Global X | 92,273 | 0 | 0 | 0 | For |
| Nationwide | 28,594 | 61,485 | 0 | 0 | Mixed |
| Investment Managers Series Trust II | 0 | 64,082 | 0 | 0 | Against |
| Voya | 57,070 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 55,991 | 0 | 0 | Against |
| T. Rowe Price | 0 | 55,067 | 0 | 0 | Against |
| AQR | 0 | 41,896 | 0 | 0 | Against |
| Pacific Life | 40,292 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 39,850 | 0 | 0 | 0 | For |
| Goldman Sachs | 37,079 | 0 | 0 | 0 | For |
| Russell Investments | 36,657 | 0 | 0 | 0 | For |
Fund voting reports, all 47 managers: 15,782,424 for, 952,656 against, 9,035 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,578,870 | 1,571 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,451,963 | 0 | 0 | 0 | For |
| Nuveen | 1,977,509 | 0 | 0 | 0 | For |
| State Street | 1,476,818 | 8,045 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 0 | 1,108,735 | 0 | 0 | Against |
| KENNEDY CAPITAL MANAGEMENT LLC | 0 | 871,149 | 0 | 0 | Against |
| Charles Schwab | 862,751 | 0 | 0 | 0 | For |
| Vanguard | 657,055 | 34,006 | 0 | 0 | For |
| MACKENZIE FINANCIAL CORP | 664,662 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 533,895 | 0 | 0 | Against |
| DE Shaw | 0 | 407,973 | 0 | 0 | Against |
| TRUST CO OF OKLAHOMA | 392,550 | 0 | 0 | 0 | For |
| AQR | 0 | 350,384 | 0 | 0 | Against |
| Goldman Sachs | 275,004 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 247,091 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 205,440 | 0 | 0 | Against |
| AllianceBernstein | 0 | 167,530 | 0 | 0 | Against |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0 | 151,743 | 0 | 0 | Against |
| Green Alpha Advisors, LLC | 0 | 127,495 | 0 | 0 | Against |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 126,000 | 0 | 0 | Against |
| JPMorgan | 121,456 | 0 | 0 | 0 | For |
| Allianz | 0 | 118,050 | 0 | 0 | Against |
| SEI | 109,346 | 0 | 0 | 0 | For |
| Fidelity | 100,133 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 98,211 | 0 | 0 | Against |
Institutional-manager reports, all 202 managers: 13,489,880 for, 4,946,039 against, 2,770 abstained, 18,381 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99% Approved · of votes cast
Prior year: 97.8% for (May 29, 2025 meeting) ▲ 1.0 pts
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Editas Medicine, Inc.’s own tally for this item (“3. The selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 64,686,839 for, 774,471 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 48 asset managers below reported 16,735,025 for, 1 against, 9,035 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,326,835 | 1 | 1 | 0 | For |
| Fidelity | 2,183,498 | 0 | 0 | 0 | For |
| BlackRock | 1,960,033 | 0 | 0 | 0 | For |
| TIAA | 1,903,318 | 0 | 0 | 0 | For |
| Charles Schwab | 862,565 | 0 | 0 | 0 | For |
| JPMorgan | 588,540 | 0 | 0 | 0 | For |
| Equitable | 259,336 | 0 | 0 | 0 | For |
| Lincoln Financial | 127,677 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 126,000 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 119,137 | 0 | 0 | 0 | For |
| Brighthouse | 109,433 | 0 | 0 | 0 | For |
| SEI | 108,986 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 108,885 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 95,483 | 0 | 0 | 0 | For |
| Global X | 92,273 | 0 | 0 | 0 | For |
| Nationwide | 90,079 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 64,082 | 0 | 0 | 0 | For |
| Voya | 57,070 | 0 | 0 | 0 | For |
| Northern Trust | 55,991 | 0 | 0 | 0 | For |
| T. Rowe Price | 55,067 | 0 | 0 | 0 | For |
| AQR | 41,896 | 0 | 0 | 0 | For |
| Pacific Life | 40,292 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 39,850 | 0 | 0 | 0 | For |
| Goldman Sachs | 37,079 | 0 | 0 | 0 | For |
| Russell Investments | 36,657 | 0 | 0 | 0 | For |
Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 97,866,996 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.49% |
| 2 | Fidelity | 2.23% |
| 3 | BlackRock | 2.00% |
| 4 | TIAA | 1.94% |
| 5 | Charles Schwab | 0.88% |
| 6 | JPMorgan | 0.60% |
| 7 | Equitable | 0.26% |
| 8 | Lincoln Financial | 0.13% |
| 9 | BRIDGEWAY FUNDS INC | 0.13% |
| 10 | AIG/SunAmerica | 0.12% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 3.66% |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 2.51% |
| 3 | Nuveen | 2.02% |
| 4 | State Street | 1.52% |
| 5 | ACADIAN ASSET MANAGEMENT LLC | 1.13% |
| 6 | KENNEDY CAPITAL MANAGEMENT LLC | 0.89% |
| 7 | Charles Schwab | 0.88% |
| 8 | Vanguard | 0.71% |
| 9 | MACKENZIE FINANCIAL CORP | 0.68% |
| 10 | Northern Trust | 0.55% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Commodore Capital LP | 16,045,802 | 16.40% | Schedule 13G, filed June 2, 2026 |
| TCG Crossover GP III, LLC | 15,798,999 | 16.14% | Schedule 13G, filed June 3, 2026 |
| BlackRock | 9,263,312 | 9.47% | Form 13F, quarter ended March 31, 2026 |
| RA Capital Management, L.P. | 8,889,000 | 9.08% | Schedule 13G, filed June 3, 2026 |
| Vanguard Group | 8,208,068 | 8.39% | Form 13F, quarter ended March 31, 2026 |
| Renaissance Technologies | 3,972,160 | 4.06% | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 2,311,789 | 2.36% | Form 13F, quarter ended March 31, 2026 |
| State Street | 2,076,122 | 2.12% | Form 13F, quarter ended March 31, 2026 |
| JPMorgan Chase | 1,947,384 | 1.99% | Form 13F, quarter ended March 31, 2026 |
| D.E. Shaw | 1,943,893 | 1.99% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 97,866,996 shares outstanding, as reported by Editas Medicine, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Editas Medicine, Inc.'s shareholder meeting held June 17, 2026, in the 2025-2026 proxy season, 237 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 840 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE… — Editas Medicine, Inc.'s filing reports the proposal as approved, with 84% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Editas Medicine, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Editas Medicine, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Editas Medicine, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Editas Medicine (EDIT) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/editas-medicine-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.